中国老年SARS-CoV-2与甲型流感病毒合并感染患者的抗病毒治疗：病例系列
Antiviral Treatment in Older Chinese Patient with SARS-CoV-2 and Influenza A Virus Co-Infection: A Case Series.
作者信息
Yang Wenjuan, Han Bing, Zheng Bei, Li Ying, Yao Tiefei, Han Mei, Li Gonghua, Zhang Meiling
机构信息
Department of Pharmacy, Tongde Hospital of ZheJiang Province, Hangzhou, Zhejiang, People's Republic of China.
Zhejiang Academy of Traditional Chinese Medicine, Hangzhou, Zhejiang, People's Republic of China.
出版信息
Infect Drug Resist. 2023 Jul 21;16:4763-4768. doi: 10.2147/IDR.S418178. eCollection 2023.
Coronavirus disease 2019 (COVID-19) emergence in late 2019, and wide spread quickly in the world. In China, the COVID-19 epidemic situation entered a low level now. With the arrival of flu season, the number of patients with respiratory symptoms is increasing. We reported three cases of patients who co-infected with SARS-CoV-2 and influenza A virus (IAV), and they were all treated with nirmatrelvir-ritonavir (NMV/r) and baloxavir marboxil. Due to the overlapping clinical features between the two diseases, it is important to identified them and gave the antiviral therapy timely.
2019年冠状病毒病（COVID-19）于2019年末出现，并迅速在全球蔓延。在中国，COVID-19疫情目前已进入低水平。随着流感季节的到来，出现呼吸道症状的患者数量正在增加。我们报告了3例同时感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）和甲型流感病毒（IAV）的患者，他们均接受了奈玛特韦-利托那韦（NMV/r）和巴洛沙韦酯治疗。由于这两种疾病临床特征重叠，因此识别它们并及时给予抗病毒治疗很重要。
Zotero 插件